The intestinal permeability marker FITC-dextran 4kDa should be dosed according to lean body mass in obese mice

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The intestinal permeability marker FITC-dextran 4kDa should be dosed according to lean body mass in obese mice. / Voetmann, Louise M.; Rolin, Bidda; Kirk, Rikke K.; Pyke, Charles; Hansen, Axel K.

In: Nutrition and Diabetes, Vol. 13, 1, 2023.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Voetmann, LM, Rolin, B, Kirk, RK, Pyke, C & Hansen, AK 2023, 'The intestinal permeability marker FITC-dextran 4kDa should be dosed according to lean body mass in obese mice', Nutrition and Diabetes, vol. 13, 1. https://doi.org/10.1038/s41387-022-00230-2

APA

Voetmann, L. M., Rolin, B., Kirk, R. K., Pyke, C., & Hansen, A. K. (2023). The intestinal permeability marker FITC-dextran 4kDa should be dosed according to lean body mass in obese mice. Nutrition and Diabetes, 13, [1]. https://doi.org/10.1038/s41387-022-00230-2

Vancouver

Voetmann LM, Rolin B, Kirk RK, Pyke C, Hansen AK. The intestinal permeability marker FITC-dextran 4kDa should be dosed according to lean body mass in obese mice. Nutrition and Diabetes. 2023;13. 1. https://doi.org/10.1038/s41387-022-00230-2

Author

Voetmann, Louise M. ; Rolin, Bidda ; Kirk, Rikke K. ; Pyke, Charles ; Hansen, Axel K. / The intestinal permeability marker FITC-dextran 4kDa should be dosed according to lean body mass in obese mice. In: Nutrition and Diabetes. 2023 ; Vol. 13.

Bibtex

@article{b1f44f5e80664553a898a6da57b0783a,
title = "The intestinal permeability marker FITC-dextran 4kDa should be dosed according to lean body mass in obese mice",
abstract = "Aims: To investigate the influence of the dose in the FITC-Dextran 4kDa (FD-4) permeability test in an obese mouse model, we tested the bodyweight dose regimen and a lean body mass-based dose regimen in high fat diet (HFD) mice and low fat diet (LFD) mice. We hypothesized that the FD-4 permeation result would be dose-dependent. Methods: The two dose regimens were compared in HFD and LFD mice. Furthermore, we conducted a dose-response study to test the effect of a low or high dose of FD-4 in weight-stratified lean mice. Gene analysis of tight junctions was also carried out. Results: The FD-4 intestinal permeability test was dose-dependent as we found a significant increase in plasma levels of FD-4 in obese mice with the bodyweight dose regimen. However, this difference was not detectable with the lean body mass dose regimen, even with variability-adjusted group sizes. However, the qPCR analysis revealed a decrease in tight junction gene expression in obese mice. Furthermore, we found a dose-dependent significant increase in FD-4 measured in plasma samples in lean mice. No significant difference in intestinal weight was observed between lean and obese mice. Conclusion: Evaluation of the intestinal permeability by FD-4 with the typical bodyweight dose regimen in obese mice will be confounded by the significant difference in dose given when compared to a lean control group. If the test dose is based on lean body mass, no significant difference in intestinal permeability is observed, even with large group sizes. Furthermore, we showed a dose-dependent difference in plasma FD-4 levels in lean mice. Therefore, we conclude that the dose should be based on lean body mass for the FD-4 permeability test if mice with considerable obesity differences are to be compared or to use another test with fixed doses. [Figure not available: see fulltext.].",
author = "Voetmann, {Louise M.} and Bidda Rolin and Kirk, {Rikke K.} and Charles Pyke and Hansen, {Axel K.}",
note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",
year = "2023",
doi = "10.1038/s41387-022-00230-2",
language = "English",
volume = "13",
journal = "Nutrition and Diabetes",
issn = "2044-4052",
publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - The intestinal permeability marker FITC-dextran 4kDa should be dosed according to lean body mass in obese mice

AU - Voetmann, Louise M.

AU - Rolin, Bidda

AU - Kirk, Rikke K.

AU - Pyke, Charles

AU - Hansen, Axel K.

N1 - Publisher Copyright: © 2023, The Author(s).

PY - 2023

Y1 - 2023

N2 - Aims: To investigate the influence of the dose in the FITC-Dextran 4kDa (FD-4) permeability test in an obese mouse model, we tested the bodyweight dose regimen and a lean body mass-based dose regimen in high fat diet (HFD) mice and low fat diet (LFD) mice. We hypothesized that the FD-4 permeation result would be dose-dependent. Methods: The two dose regimens were compared in HFD and LFD mice. Furthermore, we conducted a dose-response study to test the effect of a low or high dose of FD-4 in weight-stratified lean mice. Gene analysis of tight junctions was also carried out. Results: The FD-4 intestinal permeability test was dose-dependent as we found a significant increase in plasma levels of FD-4 in obese mice with the bodyweight dose regimen. However, this difference was not detectable with the lean body mass dose regimen, even with variability-adjusted group sizes. However, the qPCR analysis revealed a decrease in tight junction gene expression in obese mice. Furthermore, we found a dose-dependent significant increase in FD-4 measured in plasma samples in lean mice. No significant difference in intestinal weight was observed between lean and obese mice. Conclusion: Evaluation of the intestinal permeability by FD-4 with the typical bodyweight dose regimen in obese mice will be confounded by the significant difference in dose given when compared to a lean control group. If the test dose is based on lean body mass, no significant difference in intestinal permeability is observed, even with large group sizes. Furthermore, we showed a dose-dependent difference in plasma FD-4 levels in lean mice. Therefore, we conclude that the dose should be based on lean body mass for the FD-4 permeability test if mice with considerable obesity differences are to be compared or to use another test with fixed doses. [Figure not available: see fulltext.].

AB - Aims: To investigate the influence of the dose in the FITC-Dextran 4kDa (FD-4) permeability test in an obese mouse model, we tested the bodyweight dose regimen and a lean body mass-based dose regimen in high fat diet (HFD) mice and low fat diet (LFD) mice. We hypothesized that the FD-4 permeation result would be dose-dependent. Methods: The two dose regimens were compared in HFD and LFD mice. Furthermore, we conducted a dose-response study to test the effect of a low or high dose of FD-4 in weight-stratified lean mice. Gene analysis of tight junctions was also carried out. Results: The FD-4 intestinal permeability test was dose-dependent as we found a significant increase in plasma levels of FD-4 in obese mice with the bodyweight dose regimen. However, this difference was not detectable with the lean body mass dose regimen, even with variability-adjusted group sizes. However, the qPCR analysis revealed a decrease in tight junction gene expression in obese mice. Furthermore, we found a dose-dependent significant increase in FD-4 measured in plasma samples in lean mice. No significant difference in intestinal weight was observed between lean and obese mice. Conclusion: Evaluation of the intestinal permeability by FD-4 with the typical bodyweight dose regimen in obese mice will be confounded by the significant difference in dose given when compared to a lean control group. If the test dose is based on lean body mass, no significant difference in intestinal permeability is observed, even with large group sizes. Furthermore, we showed a dose-dependent difference in plasma FD-4 levels in lean mice. Therefore, we conclude that the dose should be based on lean body mass for the FD-4 permeability test if mice with considerable obesity differences are to be compared or to use another test with fixed doses. [Figure not available: see fulltext.].

U2 - 10.1038/s41387-022-00230-2

DO - 10.1038/s41387-022-00230-2

M3 - Journal article

C2 - 36604407

AN - SCOPUS:85145645530

VL - 13

JO - Nutrition and Diabetes

JF - Nutrition and Diabetes

SN - 2044-4052

M1 - 1

ER -

ID: 333616032